Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.56 |
| ▸ | HPGDS | O60760 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CFTR | P13569 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4569181 | 0.85 | HDAC1 (0.71) | HDAC6HDAC1HPGDSHDAC3HDAC2 | |
| SCHEMBL28666318 | 0.85 | MGAM (0.65) | MGAMBCAT1HDAC1KDRHPGDS | |
| SCHEMBL6237473 | 0.85 | MGAM (0.65) | MGAMHDAC6BCAT1HDAC1KDR | |
| SCHEMBL22389 | 0.85 | PLK1 (0.65) | MGAMBCAT1HDAC1KDRHPGDS | |
| SCHEMBL28901564 | 0.83 | MGAM (0.68) | MGAMBCAT1KDRHPGDSNPC1 | |
| SCHEMBL30958690 | 0.82 | KDR (0.73) | MGAMHDAC6BCAT1HDAC1KDR | |
| SCHEMBL327090 | 0.82 | KDR (0.73) | MGAMHDAC6BCAT1HDAC1KDR | |
| SCHEMBL7371232 | 0.82 | MGAM (0.76) | MGAMBCAT1KDRHPGDSNPC1 | |
| SCHEMBL19616459 | 0.82 | KDR (0.81) | HDAC6KDRNPC1RAB9AALDH1A1 | |
| SCHEMBL29647749 | 0.82 | KDR (0.81) | HDAC6KDRNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513421-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | claimed |
| EP-1868998-B1 | NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | VFP THERAPIES (FR) | 2016-05-25 | — | — | EP | disclosed |
| WO-2011146591-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-7977354-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | INSA ROUEN (FR) | 2011-07-12 | — | — | US | disclosed |
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | INSA ROUEN (FR) | 2009-03-05 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1868998-A2 | NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | Insa Rouen (FR) | 2007-12-26 | — | — | EP | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| EP-1731507-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | Institut National des Sciences Appliquees de Rouen (INSA) (FR) | 2006-12-13 | — | — | EP | disclosed |
| WO-2006103120-A2 | NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | INSA ROUEN (FR) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | NLN, SNCA, APP | MGAM 3096/4885HDAC6 542/4885BCAT1 2249/4885 |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | HAVCR2, GLS2, EIF2AK2 | MGAM 4335/4885HDAC6 55/4885BCAT1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.